HUP0600235A3 - Combinations comprising a selective cyclooxygenase-2 inhibitor - Google Patents

Combinations comprising a selective cyclooxygenase-2 inhibitor

Info

Publication number
HUP0600235A3
HUP0600235A3 HU0600235A HUP0600235A HUP0600235A3 HU P0600235 A3 HUP0600235 A3 HU P0600235A3 HU 0600235 A HU0600235 A HU 0600235A HU P0600235 A HUP0600235 A HU P0600235A HU P0600235 A3 HUP0600235 A3 HU P0600235A3
Authority
HU
Hungary
Prior art keywords
inhibitor
combinations
selective cyclooxygenase
cyclooxygenase
selective
Prior art date
Application number
HU0600235A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HUP0600235A2 publication Critical patent/HUP0600235A2/hu
Publication of HUP0600235A3 publication Critical patent/HUP0600235A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HU0600235A 2001-10-25 2002-10-24 Combinations comprising a selective cyclooxygenase-2 inhibitor HUP0600235A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34473401P 2001-10-25 2001-10-25
US34473501P 2001-10-25 2001-10-25
US33603301P 2001-11-15 2001-11-15
PCT/EP2002/011924 WO2003035047A2 (en) 2001-10-25 2002-10-24 Combinations comprising a selective cyclooxygenase-2 inhibitor

Publications (2)

Publication Number Publication Date
HUP0600235A2 HUP0600235A2 (en) 2007-02-28
HUP0600235A3 true HUP0600235A3 (en) 2008-04-28

Family

ID=27407094

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0600235A HUP0600235A3 (en) 2001-10-25 2002-10-24 Combinations comprising a selective cyclooxygenase-2 inhibitor

Country Status (22)

Country Link
US (2) US20050043409A1 (enExample)
EP (1) EP1441714B1 (enExample)
JP (1) JP2005506366A (enExample)
KR (1) KR100954625B1 (enExample)
CN (1) CN100506224C (enExample)
AT (1) ATE381930T1 (enExample)
AU (2) AU2006252156A1 (enExample)
BR (1) BR0213486A (enExample)
CA (1) CA2464309C (enExample)
CY (1) CY1108045T1 (enExample)
DE (1) DE60224299T2 (enExample)
DK (1) DK1441714T3 (enExample)
ES (1) ES2295428T3 (enExample)
HU (1) HUP0600235A3 (enExample)
IL (1) IL161462A0 (enExample)
MX (1) MXPA04003878A (enExample)
NZ (2) NZ552335A (enExample)
PL (1) PL369305A1 (enExample)
PT (1) PT1441714E (enExample)
RU (1) RU2333754C2 (enExample)
SI (1) SI1441714T1 (enExample)
WO (1) WO2003035047A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0223341D0 (en) * 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
ATE412655T1 (de) 2003-08-29 2008-11-15 Pfizer Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
JP2007505938A (ja) * 2003-09-23 2007-03-15 ノバルティス アクチエンゲゼルシャフト Ｖｅｇｆ受容体阻害剤と化学療法剤の組み合わせ
EP1667721A2 (en) * 2003-09-23 2006-06-14 Novartis AG Combinations of a vegf receptor inhibitor with other therapeutic agents
AP2006003619A0 (en) 2003-12-23 2006-06-30 Pfizer Novel quinoline derivatives
JO2596B1 (en) * 2004-11-30 2011-02-27 نوفارتيس ايه جي Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
WO2007091622A1 (ja) * 2006-02-09 2007-08-16 Daiichi Sankyo Company, Limited 抗癌医薬組成物
EP2065054A1 (en) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
CA2855243C (en) 2011-11-11 2020-04-14 Novartis Ag Method of treating a proliferative disease
MD565Z (ro) * 2012-05-23 2013-07-31 Институт Генетики, Физиологии И Защиты Растений Академии Наук Молдовы Procedeu de tratare a seminţelor de sfeclă de zahăr

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2224222T3 (es) * 1996-10-15 2005-03-01 G.D. Searle Llc Metodo de uso de inhibidores de la ciclooxigenasa-2 en el tratamiento y prevencion de neoplasias.
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
NZ333399A (en) * 1997-12-24 2000-05-26 Sankyo Co Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
AU783992B2 (en) * 1998-12-23 2006-01-12 G.D. Searle Llc Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
NZ517120A (en) * 1999-08-12 2004-10-29 Wyeth Corp NSAID and EFGR kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer
DZ3246A1 (fr) * 1999-12-03 2001-06-07 Pfizer Prod Inc Dérivé heterocyclo-alkylsulfonyle pyrazole en tant qu'agents anti-inflammatoires/analgesiques
ITMI992711A1 (it) * 1999-12-27 2001-06-27 Novartis Ag Composti organici
EP1259237A4 (en) * 2000-02-17 2004-07-28 Merck & Co Inc TREATMENT AND PROPHYLAXIS OF PROSTATE CANCER WITH COX-2 SELECTIVE INHIBITORS
CA2400923A1 (en) * 2000-02-25 2001-08-30 Merck & Co., Inc. Tyrosine kinase inhibitors
JP2003525288A (ja) * 2000-03-03 2003-08-26 ファイザー・プロダクツ・インク 抗炎症剤／鎮痛剤としてのピラゾールエーテル誘導体
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer

Also Published As

Publication number Publication date
BR0213486A (pt) 2005-05-10
AU2010200433A1 (en) 2010-02-25
ATE381930T1 (de) 2008-01-15
ES2295428T3 (es) 2008-04-16
PT1441714E (pt) 2008-03-10
HUP0600235A2 (en) 2007-02-28
WO2003035047A2 (en) 2003-05-01
CY1108045T1 (el) 2013-09-04
US20050043409A1 (en) 2005-02-24
CA2464309A1 (en) 2003-05-01
PL369305A1 (en) 2005-04-18
DE60224299T2 (de) 2008-12-11
IL161462A0 (en) 2004-09-27
WO2003035047A3 (en) 2003-10-23
CA2464309C (en) 2012-01-03
AU2006252156A1 (en) 2007-01-18
HK1068261A1 (en) 2005-04-29
NZ552335A (en) 2008-11-28
CN1575168A (zh) 2005-02-02
RU2004116069A (ru) 2005-06-10
US20110046190A1 (en) 2011-02-24
DK1441714T3 (da) 2008-03-31
KR20040048992A (ko) 2004-06-10
RU2333754C2 (ru) 2008-09-20
NZ532418A (en) 2007-02-23
MXPA04003878A (es) 2004-07-08
DE60224299D1 (de) 2008-02-07
KR100954625B1 (ko) 2010-04-27
EP1441714A2 (en) 2004-08-04
EP1441714B1 (en) 2007-12-26
SI1441714T1 (sl) 2008-06-30
CN100506224C (zh) 2009-07-01
JP2005506366A (ja) 2005-03-03

Similar Documents

Publication Publication Date Title
HUP0600294A2 (en) Skin-permeable selective cyclooxygenase-2 inhibitor composition
AU6593601A (en) Selective heteroaryloxy-acetamide-based herbicides
AU149656S (en) A cart-housing
PL368852A1 (en) Selective herbicide comprising a tetrazolinone derivative
HUP0600235A3 (en) Combinations comprising a selective cyclooxygenase-2 inhibitor
AU8456001A (en) A thermo-stable bio-matrix
AU2002360673A8 (en) Gp41 inhibitor
GB0111759D0 (en) a tap
GB0223398D0 (en) A ship
GB2387219B (en) A grenade
GB2372959B (en) A booklet
GB2372253B (en) A render
GB0119938D0 (en) A reel
NO20042122L (no) Kombinasjoner som innbefatter en selektiv cyklooksygenase-2 inhibitor
GB0107501D0 (en) A strip
AU145695S (en) A bedroll
AU144988S (en) A drop-bolt
AU145394S (en) A cord-lock
AU143799S (en) A hatbox
AU148760S (en) A frypan
AU147766S (en) A sheet-bag
AU147171S (en) A flumegate
AU145697S (en) A bracelet
AU145696S (en) A bracelet
GB0119489D0 (en) A pipe beveller

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees